Conference 2009 - Keynote Presentation
Dr. Diane Jorkasky gave a highly relevant, provocative and out-of-the-box-thinking keynote speech at this year’s conference which has been cited and mentioned in many subsequent presentations throughout the whole event.
Here is a short list of bullet points to summarise her points:
The key asset of any pharmaceutical company is the data. Without clinical data, no compound will make it to the market, no matter how good it is.
Currently the industry is not using the data to its full potential
Well organized, structured and easily accessible data-depositories built on a compound level are rare
Consequently retrieving any kind of information over a whole compound (i.e. al patients who ever took the drug during a study) is extremely time consuming and costly, if not impossible. This because of non-standard data models, legacy servers residing on legacy servers, etc...
Usage of placebo data within a therapeutic area across compounds is hardly possible. Companies have to buy expensive placebo data to circumvent this incapability of using the already available data
Using pre-clinical data for better prediction of an optimal dose for Early Development studies could save a lot of time and effort.
Dr. Jorkasky proposes three strategies to improve this situation:
The video shows examples and success stories for each one of these points: